BioNTech pays $25M upfront to strengthen ADC bond with China's MediLink
28 May 2024
Preview
Source: FierceBiotech
The latest agreement between BioNTech and MediLink Therapeutics marks an expansion of the collaboration between the two companies penned in October 2023.
After penning a couple of antibody-drug conjugate (ADC) deals in 2023, BioNTech has returned to MediLink Therapeutics to further pad out its portfolio.
This time, BioNTech is handing over $25 million upfront for the chance to apply MediLink’s solid-tumor-focused TMALIN ADC platform to several undisclosed targets selected by the German biotech. Suzhou, China-based MediLink will also be in line for up to $1.8 billion in milestones.
The latest agreement marks an expansion of the collaboration between the two companies penned in October 2023. That deal saw BioNTech pay $70 million upfront for the rights to a HER3-directed ADC. MediLink began testing that candidate in non-small cell lung cancer and breast cancer late in 2022, building on preclinical evidence that the ADC delivers its cytotoxic payload to tumor cells that express HER3 without causing significant toxicity to healthy tissues.
There were $1 billion in biobucks tied to that original deal, but how much BioNTech ends up paying out depends to an extent on whether HER3 lives up to expectations that it could be the next major ADC target. Interest in HER3 is built on evidence that the receptor is involved in cancers of the lung and breast, but validation of the target is ongoing.
MediLink is not the only China-based ADC partner that BioNTech has signed on with since it identified the modality as one avenue to spend its COVID-19 billions. The German biotech, which is best known for its mRNA platform, also paid $170 million upfront in April 2023 for the rights to two ADCs in development at Duality Biologics.
For MediLink's part, BioNTech isn’t the only European drug developer to have shown an interest in its tech. Roche kicked off the year penning a more than $1 billion biobucks deal for the Chinese company’s ADC candidate targeting c-Mesenchymal epithelial transition factor (c-Met) under development for solid tumors.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.